Ruijin Hospital

This study tests a new drug (QL1706) combined with chemotherapy for people with a type of esophageal cancer that is hard to remove surgically. The goal is to shrink the tumor enough so it can be fully removed with surgery, then continue the new drug afterward to keep the cancer f…

This study tests a combination of three drugs (tazemetostat, linperlisib, and golidocitinib) in people with a type of lymphoma that has come back or stopped responding to treatment. The goal is to see if the combination can shrink tumors and control the disease. About 48 adults w…

This early-phase study tests the safety and tolerability of a new drug, cizutamig, in 15 adults with moderate to severe ulcerative colitis. Participants must have tried other treatments without success. The goal is to see if the drug is safe enough for further testing.

This study looks at a new vaccine called KSD-101 for people with blood cancers linked to the Epstein-Barr virus (EBV). The vaccine is designed to train the body's immune system to attack cancer cells. The goal is to see if it can shrink tumors or keep the cancer from coming back.…

This study tests a personalized combination of drugs for people with a type of lymphoma (PTCL) that did not respond to initial chemotherapy. Researchers will use genetic information from each patient's tumor to select the best drug combination, including an experimental drug call…

This study looks at whether giving a short course of the steroid hydrocortisone after adrenal gland surgery can help slow the decline in kidney function for patients with primary aldosteronism (a hormone disorder causing high blood pressure) who also have chronic kidney disease. …

This study tests whether adding the drug golidocitinib to standard chemotherapy (GemOx) can shrink tumors in people with a rare blood cancer called peripheral T-cell lymphoma that has returned or not responded to prior treatment. About 31 adults will receive the combination and b…

This study tests whether adding the targeted drug zanubrutinib to standard chemotherapy can improve outcomes for people newly diagnosed with central nervous system lymphoma. About 19 participants will receive the combination, and those who respond well will continue zanubrutinib …

This study tests a new drug called cadonilimab combined with radiation therapy for people with advanced cervical cancer who cannot receive standard chemotherapy due to age or health issues. The goal is to see if this combination can make tumors disappear completely. About 45 part…

This study tests if a new combination of drugs (C Pola R-CHP+X) works better than the standard treatment (CR-CHOP) for people with a fast-growing type of lymphoma called double-expressor DLBCL. The trial will include 156 adults who have not been treated before. The goal is to see…

This early-phase study tests a combination of three drugs (sonrotoclax, zanubrutinib, and obinutuzumab) as a first treatment for people newly diagnosed with an aggressive form of mantle cell lymphoma. About 28 adults with high-risk features will receive the combo to see how well …

This study compares two types of radiation therapy—proton and photon—given after breast cancer surgery to see which causes fewer side effects. Researchers will follow 750 women for one year, tracking problems like arm swelling, low immune cells, and heart issues. The goal is to f…

This study looks at blood and sputum from 411 adults with acute respiratory distress syndrome (ARDS) who need a breathing machine. Researchers will analyze genes, microbes, and chemicals in these samples to find clues about how well patients respond to treatment and their chances…

This study looks at whether a new ultrasound-based risk score can better predict pressure injuries (bedsores) in critically ill patients in the ICU. In the first phase, researchers will check how well the score works compared to traditional methods. In the second phase, some pati…